Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab.
Why EV Maker Polestar Automotive’s Shares Are Soaring Today
Shares of Polestar Automotive Holding are surging today after the company said it is expanding its global presence and enhancing its retail strategy to include both existing and new markets as its electric vehicle (EV) lineup grows.
What’s Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for relapsed/refractory B-cell malignancies
What’s Happening With US Steel Shares On Monday?
U.S. Steel forecasts Q2 2024 adjusted net earnings per share of $0.76 to $0.80, under the consensus estimate of $0.83, amidst stable domestic demand but challenging market dynamics, as detailed by CEO David B. Burritt.
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and fatigue were observed.
OpenAI And Color Health Develop AI-Driven Cancer Care Solutions: Report
OpenAI and startup Color Health have developed an AI assistant, named 'copilot', to support physicians in creating personalized cancer care plans, emphasizing the tool's role in augmenting rather than replacing human expertise.
Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday?
Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hypertension. Despite being well tolerated, AV-101 failed to meet primary and secondary endpoints. Enrollment for Phase 3 is halted.
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?
Mustang Bio shares soar 190.9% on high trading volume as Phase 1/2 trial data for CAR T-cell therapy MB-106 shows positive results.
Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients
Marinus Pharmaceuticals announces Phase 3 RAISE trial results for IV ganaxolone in refractory status epilepticus.
What’s Going On With Ovid Therapeutics After Takeda’s Two Phase 3 Epilepsy Studies Fail?
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.